Veolia Environnement Achieves 9-Month Earnings Increase

1 Mins read

Veolia Environnement, the French resource-management company, has announced that it has achieved its earnings target for the first nine months of the year. With a significant increase in sales, Veolia reported earnings before interest, taxes, depreciation, and amortization of €4.79 billion ($5.13 billion), compared to €4.53 billion in the previous year. Revenue also saw a strong growth of 11% on a like-for-like basis, reaching €33.16 billion.

Strong Performance Driven by Business Momentum

Veolia attributes its positive results to the continued business momentum carried over from the first half of the year into the third quarter. This sustained momentum, combined with solid fundamentals, such as resistance to inflation and favorable contract indexation, has contributed to Veolia’s exceptional performance.

CEO Confirms 2023 Targets

Estelle Brachlianoff, Chief Executive Officer of Veolia Environnement, expressed her confidence in the company’s future prospects. Brachlianoff stated that Veolia maintains its 2023 targets and expects Ebitda growth to be at the upper end of the projected range of 5% to 7%.

Veolia Environnement continues to demonstrate resilience in the face of economic challenges and is well-positioned for continued success.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

6 + 4 =